SLC16A1 在多种癌症类型的发展中扮演着重要的角色。泛癌症分析可能对探索 SLC16A1 基因表达、预后及肿瘤发生分子机制之间关系具有显著影响。本研究通过对 TCGA 和 GEO 数据集的分析，探讨了 SLC16A1 在泛癌症中的表达水平及生存预后，并进一步探讨了肿瘤和正常组织之间 SLC16A1 基因突变、甲基化和磷酸化的差异。此外，我们通过免疫浸润分析和富集分析，重点研究了这个基因的生物学功能以及预后和免疫浸润之间的关系，以评估 SLC16A1 在癌症中的诊断和预后意义。研究发现，SLC16A1 在14种肿瘤中高度表达，9种肿瘤的预后存在显著差异。S467 的磷酸化水平在卵巢癌、肾癌和子宫内膜癌中增加。在头颈鳞状细胞癌、肺鳞癌、肉瘤、精原细胞肿瘤和肾透明细胞癌中，CD8+ T 细胞浸润水平与 SLC16A1 表达呈负相关。BLCA、BRCA、KIRC、KIRP、PAAD、PCPG 和 THCA 中，癌相关成纤维细胞与 SLC16A1 表达呈正相关。富集分析表明，这个基因的肿瘤发生机制主要与“糖酵解和葡萄糖代谢合成”有关。SLC16A1 是一个有前途的泛癌症预后和免疫学生物标志物。Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

SLC16A1 plays an important role in the development of multiple cancer types. Pan-cancer analysis may have significant impacts on the exploration of the relationship between SLC16A1 gene expression, prognosis and the molecular mechanisms of tumorigenesis. In this study, through the analysis of TCGA and GEO datasets, we explored the expression level and survival prognosis of SLC16A1 in pan-cancer, and further explored the differences in SLC16A1 gene mutation, methylation, and phosphorylation between tumor and normal tissues. In addition, we focused on the biological function of this gene and the relationship between the prognosis and immune infiltration by immune infiltration analysis and enrichment analysis, in order to evaluate the diagnostic and prognostic significance of SLC16A1 in carcinomas. The study found that SLC16A1 was highly expressed in 14 kinds of tumors, and there were statistically significant differences in the prognosis of 9 tumors. The phosphorylation level of S467 increased in OV, RCC, and UCEC. There was a statistically negative correlation between the CD8+ T-cell infiltration level and the SLC16A1 expression in HNSC, LUSC, SARC, TGCT, and KIRC. The cancer-related fibroblasts were positively correlated with SLC16A1 expression in BLCA, BRCA, KIRC, KIRP, PAAD, PCPG, and THCA. The enrichment analysis indicated that the tumorigenesis mechanism of this gene was mainly related to "glycolysis and glucose metabolism synthesis." SLC16A1 was a promising prognostic and immunological biomarker in pan-cancer.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.